Tango Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights
Provided By GlobeNewswire
Last update: May 12, 2025
– Data update from ongoing TNG462 Phase 1/2 monotherapy trial expected 2H 2025 –
– Combination trial of TNG462 + Revolution Medicines RAS(ON) inhibitors on track for enrollment 2Q 2025 –
Read more at globenewswire.com
